Forms of administration and relevance to fertility support: Subcutaneous injection is common in research and allows local delivery near pelvic structures or systemic exposure
In our experience, patients with a subacute tendinopathy that has stalled at 6 to 12 weeks of physical therapy tend to notice a meaningful change in pain and range of motion within 3 to 4 weeks of starting a BPC-157 protocol
Youll see claims that BPC-157 peptide benefits include: quicker, more effective healing reduced joint pain reduced tendon issues less stiffness improved recovery less inflammation better gut health Basically, its promoted as a do-it-all fix
The practical takeaway: Injection = high systemic distribution tendons, ligaments, muscle, joints, vascular tissue Oral = high local GI concentration intestinal lining, gastric mucosa, gut repair Nasal = intermediate systemic delivery potential neurological targeting, emerging evidence only Injectable BPC-157: Highest Bioavailability for Systemic and Musculoskeletal Goals Injectable BPC-157 is the best-studied delivery method for healing applications outside the gastrointestinal tract
FDA advisers narrowly vote to add 6 peptides to a drug compounding list